BioCentury
ARTICLE | Financial News

Juno closes A round with $176 million

April 25, 2014 12:28 AM UTC

Juno Therapeutics Inc. (Seattle, Wash.) raised $31 million in the final tranche of a series A round, bringing the total raised in the round to $176 million. The cancer immunotherapy company initially raised $120 million in the A round in December and in January expanded the round to $145 million. Juno declined to disclose who participated in the final tranche. The company also hired Mark Frohlich as EVP of R&D. He was EVP of R&D and CMO at cancer immunotherapy company Dendreon Corp. (NASDAQ:DNDN). ...